Claims:

1. An *in vitro* method for diagnosing infantile hemangioma and/or monitoring the progress and prognosis thereof in a subject, the method comprising the steps of:

(a) providing a blood sample obtained from the subject;

(b) quantifying the concentration levels of at least one fatty acid in the biological sample, wherein the fatty acid is total fatty acid or total saturated fatty acid or total monounsaturated fatty acid or at least one of the fatty acids selected from the group consisting of C10:0, C11:0, C12:0, C14:0, C15:0, C15:1N5, C16:0, C17:0, C18:0, C18:2N6, C20:0, C20:3N3, C20:5N3, C21:0, C22:1N9, C23:0, C24:0 and C8:0;

(c) comparing the quantified concentration levels to a control comprising baseline values of said fatty acids from a normal subject or a subject with neonatal erythema; and

(d) determining that the subject has infantile hemangioma if the quantified concentration levels deviate from the control.

2. The method according to claim 1, wherein the at least one fatty acid is at least 2 fatty acids selected from the group consisting of C10:0, C11:0, C12:0, C14:0, C15:0, C15:1N5, C16:0, C17:0, C18:0, C18:2N6, C20:0, C20:3N3, C20:5N3, C21:0, C22:1N9, C23:0, C24:0 and C8:0.

3. The method according to claim 1, wherein the at least one fatty acid is at least 3 fatty acids selected from the group consisting of C10:0, C11:0, C12:0, C14:0, C15:0,

C15:1N5, C16:0, C17:0, C18:0, C18:2N6, C20:0, C20:3N3, C20:5N3, C21:0, C22:1N9, C23:0, C24:0 and C8:0.

4. The method according to claim 1, wherein the at least one fatty acid is 1-6 fatty acids selected from the group consisting of C10:0, C11:0, C12:0, C14:0, C15:0, C15:1N5, C16:0, C17:0, C18:0, C18:2N6, C20:0, C20:3N3, C20:5N3, C21:0, C22:1N9, C23:0, C24:0 and C8:0.

5. The method according to any one of claims 1-4, wherein the at least one fatty acid is selected from the group consisting of C8:0, C10:0, C11:0, C16:0, C20:0, C20:5N3, C22:1N9, C23:0 and C24:0.

6. The method according to claim 5, wherein the at least one fatty acid is selected from the group consisting of C20:5N3, C22:1N9, C23:0 and C24:0.

7. The method according to any one of claims 1-4, wherein the at least one fatty acid is selected from the group consisting of C10:0, C14:0, C16:0, C18:2N6, C20:0, C20:5N3, C22:1N9, C24:0 and C8:0.

8. The method according to claim 7, wherein the at least one fatty acid is selected from the group consisting of C10:0, C16:0, C20:0, C20:5N3 and C22:1N9.

9. The method according to claim 8, wherein the one fatty acids are C10:0, C16:0, C20:0, C20:5N3 and C22:1N9.

10. The method according to any one of Claims 1 to 9, wherein the sample is selected from the group consisting of the subject's whole blood, plasma, serum, lymphocyte

suspension, cerebrospinal fluid, bone marrow, pleural effusion, urine, saliva, and abdominal effusion.

11. The method according to any one of Claims 1 to 10, wherein the sample is selected from the group consisting of umbilical cord blood and peripheral blood.

12. A test kit for diagnosing infantile hemangioma and/or monitoring its progress and prognosis in a subject, comprising:

(a) means for determining the amount of at least one fatty acid in a biological sample from the subject, wherein the fatty acid is total fatty acid or total saturated fatty acid or total monounsaturated fatty acid or at least one of the fatty acids selected from the group consisting of C10:0, C11:0, C12:0, C14:0, C15:0, C15:1N5, C16:0, C17:0, C18:0, C18:2N6, C20:0, C20:3N3, C20:5N3, C21:0, C22:1N9, C23:0, C24:0 and C8:0; and

(b) instructions for using the kit.